Clinical experience with dual pathway inhibition therapy: case series and mini review.
Tobias GeislerKelley R H BranchSigrid NikolPublished in: European heart journal. Case reports (2022)
In eligible patients who are at high risk of cardiovascular events, DPI therapy with low-dose rivaroxaban should be considered. Treatment can be started at various times, including at the end of dual antiplatelet therapy, at routine follow-up, or after new events or diagnoses.
Keyphrases
- cardiovascular events
- antiplatelet therapy
- low dose
- end stage renal disease
- acute coronary syndrome
- coronary artery disease
- ejection fraction
- newly diagnosed
- cardiovascular disease
- chronic kidney disease
- venous thromboembolism
- prognostic factors
- pulmonary embolism
- high dose
- peritoneal dialysis
- type diabetes
- stem cells
- patient reported